The Association Between Acquired Color Deficiency and PET Imaging of Neurodegeneration in Mild Cognitive Impairment and Alzheimer Disease.

Autor:	Vidal KSM; Laboratory of Vision, Institute of Psychology, University of São Paulo, São Paulo, Brazil.; Prevent Senior Private Health Operator, São Paulo, Brazil.; Young medical Leadership Program of National Academy of Medicine in Brazil, Rio de Janeiro, Rio de Janeiro, Brazil., Decleva D; Laboratory of Vision, Institute of Psychology, University of São Paulo, São Paulo, Brazil., Barboni MTS; Laboratory of Vision, Institute of Psychology, University of São Paulo, São Paulo, Brazil.; Department of Ophthalmology, Semmelweis University, Budapest, Hungary., Nagy BV; Department of Mechatronics, Optics and Mechanical Engineering Informatics, University of Technology and Economics, Budapest, Hungary., de Menezes PAH; Prevent Senior Private Health Operator, São Paulo, Brazil., Aher A; Section for Retinal Physiology, University Hospital Erlangen, Erlangen, Germany., Coutinho AM; Laboratory of Psychiatric Neuroimaging (LIM 21), Department of Psychiatry, Medical School (FMUSP), University of São Paulo, São Paulo, Brazil.; Laboratory of Nuclear Medicine (LIM-43), Department of Radiology and Oncology, Medical School (FMUSP), University of São Paulo, São Paulo, Brazil., Squarzoni P; Laboratory of Psychiatric Neuroimaging (LIM 21), Department of Psychiatry, Medical School (FMUSP), University of São Paulo, São Paulo, Brazil.; Núcleo de Apoio à Pesquisa em Neurociência Aplicada (NAPNA), Universidade de São Paulo, São Paulo, Brazil., Faria DP; Laboratory of Nuclear Medicine (LIM-43), Department of Radiology and Oncology, Medical School (FMUSP), University of São Paulo, São Paulo, Brazil., Duran FLS; Laboratory of Psychiatric Neuroimaging (LIM 21), Department of Psychiatry, Medical School (FMUSP), University of São Paulo, São Paulo, Brazil.; Núcleo de Apoio à Pesquisa em Neurociência Aplicada (NAPNA), Universidade de São Paulo, São Paulo, Brazil., Buchpiguel CA; Laboratory of Nuclear Medicine (LIM-43), Department of Radiology and Oncology, Medical School (FMUSP), University of São Paulo, São Paulo, Brazil., Kremers J; Section for Retinal Physiology, University Hospital Erlangen, Erlangen, Germany., Filho GB; Laboratory of Psychiatric Neuroimaging (LIM 21), Department of Psychiatry, Medical School (FMUSP), University of São Paulo, São Paulo, Brazil.; Núcleo de Apoio à Pesquisa em Neurociência Aplicada (NAPNA), Universidade de São Paulo, São Paulo, Brazil., Ventura DF; Laboratory of Vision, Institute of Psychology, University of São Paulo, São Paulo, Brazil.; Núcleo de Apoio à Pesquisa em Neurociência Aplicada (NAPNA), Universidade de São Paulo, São Paulo, Brazil.
Jazyk:	angličtina
Zdroj:	Investigative ophthalmology & visual science [Invest Ophthalmol Vis Sci] 2022 May 02; Vol. 63 (5), pp. 20.
DOI:	10.1167/iovs.63.5.20
Abstrakt:	Purpose: To evaluate color vision changes and retinal processing of chromatic and luminance pathways in subjects with Alzheimer disease (AD) and mild cognitive impairment (MCI) compared with a matched control group and whether such changes are associated with impaired brain glucose metabolism and β-amyloid deposition in the brain. Methods: We evaluated 13 patients with AD (72.4 ± 7.7 years), 23 patients with MCI (72.5 ± 5.5 years), and 18 controls of comparable age (P = 0.44) using Cambridge color test and the heterochromatic flicker ERG (HF-ERG). The Cambridge color test was performed using the trivector protocol to estimate the protan, deutan and tritan color confusion axes. HF-ERG responses were measured at a frequency of 12 Hz, which ERGs reflect chromatic activity, and at 36 Hz, reflecting luminance pathway. A study subsample was performed using neuropsychological assessments and positron emission tomography. Results: Patients with AD presented higher mean values indicating poorer color discrimination for protan (P = 0.04) and deutan (P = 0.001) axes compared with the controls. Along the tritan axis, both patients with AD and patients with MCI showed decreased color vision (P = 0.001 and P = 0.001) compared with controls. The analyses from the HF-ERG protocol revealed no differences between the groups (P = 0.31 and P = 0.41). Diffuse color vision loss was found in individuals with signs of neurodegeneration (protan P = 0.002, deutan P = 0.003 and tritan P = 0.01), but not in individuals with signs of β-amyloid deposition only (protan P = 0.39, deutan P = 0.48, tritan P = 0.63), regardless of their clinical classification. Conclusions: Here, patients with AD and patients with MCI present acquired color vision deficiency that may be linked with impaired brain metabolism.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu